TrialJournal of hematology & oncology2025

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

Jorge E Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.